Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,640 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2 Interventional Results available

Tezepelumab COPD Exacerbation Study

NCT04039113
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
27
States / cities
Dothan, Alabama • Huntington Beach, California • Newport Beach, California + 24 more
Conditions
Pulmonary Artery Hypertension
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Terminated Not applicable Interventional Results available

Feasibility of At-Home Handheld Spirometry

NCT03284203
Conditions
COPD
Interventions
SpiroPD
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 85 Years
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
92
States / cities
Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Completed Phase 3 Interventional Results available

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

NCT02796677
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg), Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg, Tiotropium 18 μg (TIO 18 μg), Placebo to TIO 18 μg
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
85
States / cities
Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
Completed Not applicable Interventional Results available

Differentiating the Effects of Substance P and Beta-endorphin

NCT01854177
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Cystic Fibrosis, Chronic Bronchitis
Interventions
IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
MedImmune LLC
Industry
Eligibility
40 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Baltimore, Maryland • Springfield, Massachusetts • St Louis, Missouri + 6 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Bevespi, Bretzri
Drug
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
17,183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
303
States / cities
Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 243 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
11
States / cities
Anaheim, California • Los Angeles, California • Panama City, Florida + 8 more
Conditions
Chronic Graft Versus Host Disease
Interventions
Fostamatinib, Ruxolitinib
Drug
Lead sponsor
Stefanie Sarantopoulos, MD, PhD.
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Terminated No phase listed Observational Accepts healthy volunteers

Smoking-induced EGF-dependent Reprogramming of Airway Basal Cell Function

NCT01974180
Conditions
Smoking, COPD, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Migraine
Interventions
CVT-427 (zolmitriptan inhalation powder)
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
North Dartmouth, Massachusetts • Lincoln, Nebraska • Dallas, Texas
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Anti-Platelets in Chronic Obstructive Pulmonary Disease

NCT05567562
Conditions
COPD, Emphysema, Emphysema or COPD
Interventions
dual anti-platelet therapy, Placebo
Combination Product · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Granulomatous Disease, Chronic
Interventions
Busulfan
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders, Pulmonary Disease, Chronic Obstructive Lung Diseases, Chronic Obstructive Airway Disease
Interventions
Roflumilast, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
2,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
217
States / cities
Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
50 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BCT197, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
40 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Michigan City, Indiana • Baltimore, Maryland • Milwaukee, Wisconsin
Conditions
COPD, Diabetes, Hypertension
Interventions
Supportive counseling, Education on SMB, Psychoeducation on ATs for maladaptive beliefs (if applicable), Psychoeducation on emotional response (if applicable)
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Conditions
Sleep Apnea Syndrome, Obstructive Sleep Apnea, COPD, Overlap Syndrome, Quality of Life, Neurocognitive Function, Sleepiness, Elderly, Positive Airway Pressure
Interventions
Positive airway pressure, Conservative care (control arm)
Device · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Chronic Obstructive Pulmonary Disease, Emphysema
Interventions
Effectiveness of Lung Reduction Therapy
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Up to 75 Years · Male only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Smoking, Pulmonary Disease, Chronic Obstructive, Tobacco Use Disorder
Interventions
Standard Smoking Cessation, Extended Nicotine Replacement Therapy, Nicotine replacement therapy
Other · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas